{"id":2696,"date":"2016-03-17T09:20:51","date_gmt":"2016-03-17T08:20:51","guid":{"rendered":"http:\/\/wordpress.p545550.webspaceconfig.de\/uncategorized\/2687\/"},"modified":"2020-08-26T07:19:55","modified_gmt":"2020-08-26T05:19:55","slug":"2687","status":"publish","type":"post","link":"https:\/\/www.izb-online.de\/en\/2687\/","title":{"rendered":"Strong business year for Morphosys"},"content":{"rendered":"

[vc_row el_class=”gco-magazine-container”][vc_column el_class=”bildspalte”][vc_row_inner][vc_column_inner offset=”vc_col-lg-12 vc_col-md-12″][vc_column_text el_class=”gco-magazine–title”]<\/p>\n

Strong business year for Morphosys<\/h1>\n

[\/vc_column_text][vc_column_text el_class=”gco-magazine–post-date”]March 2017[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_single_image image=”2689″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright-without-description”]\u00a9 MorphoSys[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy”][vc_column_inner][vc_column_text]\u201d2016 was a successful year for Morphosys. We applied for market approval through our pharmaceutical partner Janssen for the first therapeutic antibody based on our technology. We expect to hear the decision on the approval of Guselkumab in the second half of 2017,\u201d said Morphosys CEO Dr. Simon Moroney, commenting on the successful business year 2016. At the same time, according to Moroney, the biotech company now resident at the new attractive location in Steinkirchen \u201chas achieved great progress with our own development candidates. In our pipeline we see many active compounds that have the potential to create new standards in the treatment of diseases \u2013 to the benefit of all our stakeholders, such as our partners, shareholders and above all patients. With a record number of 114 programs in research and development, our active compound portfolio is one of the broadest in the biopharmaceutical industry,\u201d says Moroney.[\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine–quote” css=”.vc_custom_1593681289788{margin-bottom: 45px !important;}”][vc_column_inner][vc_single_image image=”2692″ img_size=”155×155″ alignment=”center” style=”vc_box_circle_2″][vc_column_text el_class=”gco-magazine–picture-discription-blank”]Dr.Simon Moroney,
\nCEO, MorphoSys AG[\/vc_column_text][vc_column_text el_class=”gco-magazine-copyright-blank”]<\/p>\n

\u00a9 MorphoSys<\/p>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner]\n\n

\n \n \n
\n MorphoSys AG <\/div>\n\n